Benzinga · Aug 5, 2026
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.
LR
NASDAQ · LRMR
Larimar Therapeutics, Inc.
Healthcare · Biotechnology
$3.85
Down-$0.02 (-0.52%)
Updated Sep 11, 2026, 3:49 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 343.65M
- P/E ratio
- -2.58
- Dividend yield
- 0.00%
- 52-week range
- $2.92 – $6.00
- Volume
- 871.39K
- Avg. volume
- 2.64M
Price performance
LRMR price history
1M range · 20 trading sessions · Daily adjusted prices
LRMR closed at $3.85 after 20 trading sessions, down 9.84% for the selected period.
- Last close
- $3.85
- Period change
- -9.84%
- Period low
- $3.82
- Period high
- $4.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $3.82 | $3.86 | $3.74 | $3.85 | 871.39K |
| Sep 9, 2026 | $4.03 | $4.17 | $3.83 | $3.87 | 978.8K |
| Sep 8, 2026 | $3.76 | $4.08 | $3.72 | $4.075 | 1.04M |
| Sep 4, 2026 | $3.82 | $3.85 | $3.79 | $3.83 | 391.99K |
| Sep 3, 2026 | $3.90 | $3.90 | $3.7741 | $3.83 | 684.26K |
| Sep 2, 2026 | $3.96 | $4.075 | $3.8218 | $3.87 | 515.56K |
| Sep 1, 2026 | $3.78 | $3.95 | $3.77 | $3.94 | 755.35K |
| Aug 31, 2026 | $3.98 | $4.00 | $3.81 | $3.82 | 1.07M |
| Aug 28, 2026 | $4.03 | $4.08 | $3.98 | $4.01 | 641.51K |
| Aug 27, 2026 | $4.16 | $4.16 | $4.02 | $4.05 | 673.59K |
| Aug 26, 2026 | $4.14 | $4.18 | $4.02 | $4.17 | 702.14K |
| Aug 25, 2026 | $4.08 | $4.235 | $4.08 | $4.16 | 1.08M |
| Aug 24, 2026 | $4.23 | $4.23 | $3.93 | $4.05 | 945.55K |
| Aug 21, 2026 | $4.20 | $4.21 | $4.085 | $4.18 | 699.42K |
| Aug 20, 2026 | $4.21 | $4.21 | $3.975 | $4.16 | 1.16M |
| Aug 19, 2026 | $4.19 | $4.34 | $4.17 | $4.25 | 1.23M |
| Aug 18, 2026 | $4.31 | $4.35 | $4.05 | $4.06 | 869.63K |
| Aug 17, 2026 | $4.33 | $4.4199 | $4.30 | $4.32 | 882.8K |
| Aug 14, 2026 | $4.26 | $4.39 | $4.17 | $4.36 | 1.18M |
| Aug 13, 2026 | $4.38 | $4.465 | $4.23 | $4.27 | 1.5M |
Latest LRMR news
The latest Smart Investors Daily articles mentioning LRMR.
Stock researchCompany · Overview
LRMR research
Overview
Company profile and research snapshot.
Company profile
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $7.00
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Wedbush | Outperform | — |
| Jun 30, 2026 | Baird | Outperform | — |
| May 27, 2026 | JP Morgan | Overweight | — |
| May 18, 2026 | Wedbush | Outperform | — |
| Mar 20, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 4, 2026
Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses of $(0.41) per share
Benzinga · Jul 2, 2026
HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) with a Buy rating and announces Price Target of $10.
SeekingAlpha · Jul 1, 2026
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia - Slideshow
2026-07-01. The following slide deck was published by Larimar Therapeutics, Inc.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
